Naomi Kiyota Selected Research

Tyrosine Kinase Inhibitors

4/2022	Systemic therapy for salivary gland malignancy: current status and future perspectives.
12/2019	Discontinuation of sorafenib can lead to the emergence of FLT3-ITD-positive acute myeloid leukemia.
4/2018	Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry imaging.
10/2013	Hypothyroidism in patients with colorectal carcinoma treated with fluoropyrimidines.
1/2013	Regulation of MET kinase inhibitor resistance by copy number of MET in gastric carcinoma cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Naomi Kiyota Research Topics

Disease

53	Neoplasms (Cancer) 03/2024 - 06/2012
28	Squamous Cell Carcinoma of Head and Neck 03/2024 - 04/2009
19	Thyroid Neoplasms (Thyroid Cancer) 02/2024 - 02/2015
15	Head and Neck Neoplasms (Head and Neck Cancer) 01/2023 - 04/2009
10	Neoplasm Metastasis (Metastasis) 06/2022 - 02/2008
7	Exanthema (Rash) 10/2022 - 10/2017
7	Carcinoma (Carcinomatosis) 04/2022 - 11/2012
7	Breast Neoplasms (Breast Cancer) 03/2022 - 04/2013
7	Disease Progression 02/2021 - 02/2015
5	Squamous Cell Carcinoma (Epidermoid Carcinoma) 10/2023 - 01/2016
5	Fatigue 06/2022 - 06/2012
5	Stomatitis 01/2020 - 04/2009
5	Stomach Neoplasms (Stomach Cancer) 01/2014 - 08/2012
4	Anaplastic Thyroid Carcinoma 01/2022 - 01/2017
4	Pancreatic Neoplasms (Pancreatic Cancer) 01/2021 - 01/2014
4	Pain (Aches) 01/2020 - 01/2014
4	Hypertension (High Blood Pressure) 09/2018 - 02/2015
3	Infections 10/2022 - 05/2016
3	Papillary Thyroid Cancer 12/2019 - 09/2018
3	Diarrhea 08/2019 - 02/2008
3	Lymphatic Metastasis 04/2019 - 12/2018
3	Tongue Neoplasms (Tongue Neoplasm) 04/2019 - 08/2017
3	Hypopharyngeal Neoplasms 01/2019 - 01/2017
3	Proteinuria 12/2018 - 12/2015
3	Mucositis 12/2018 - 12/2016
3	Nausea 10/2017 - 04/2009
2	Hypoparathyroidism 11/2023 - 12/2020
2	COVID-19 01/2023 - 04/2022
2	Esophageal Neoplasms (Esophageal Cancer) 10/2021 - 12/2016
2	Febrile Neutropenia 09/2021 - 02/2008
2	Sarcoma (Soft Tissue Sarcoma) 04/2021 - 01/2021
2	Colorectal Neoplasms (Colorectal Cancer) 02/2021 - 10/2013
2	Neutropenia 01/2021 - 02/2008
2	medullary Thyroid cancer 01/2020 - 03/2019
2	Deglutition Disorders (Dysphagia) 12/2019 - 01/2017
2	Cachexia 01/2019 - 01/2014
2	Oropharyngeal Neoplasms 01/2019 - 12/2018
2	Body Weight (Weight, Body) 11/2016 - 12/2015
2	Hypothyroidism 10/2013 - 06/2012
2	Leukopenia 04/2009 - 02/2008
1	Disease Susceptibility (Diathesis) 01/2023
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2023
1	Hypophysitis 01/2023

Drug/Important Bio-Agent (IBA)

22	Cisplatin (Platino)FDA LinkGeneric 03/2024 - 04/2009
19	lenvatinibIBA 01/2022 - 02/2015
12	NivolumabIBA 01/2023 - 11/2016
9	Fluorouracil (Carac)FDA LinkGeneric 10/2023 - 04/2009
9	Docetaxel (Taxotere)FDA Link 10/2023 - 02/2008
8	Phosphotransferases (Kinase)IBA 02/2021 - 08/2012
7	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 02/2024 - 06/2012
7	PlatinumIBA 01/2022 - 11/2016
5	Tyrosine Kinase InhibitorsIBA 04/2022 - 01/2013
4	Cetuximab (Erbitux)FDA Link 01/2023 - 11/2016
4	Sorafenib (BAY 43-9006)FDA Link 12/2019 - 01/2014
4	Biomarkers (Surrogate Marker)IBA 05/2018 - 06/2012
3	Immune Checkpoint InhibitorsIBA 01/2023 - 09/2020
3	AntibodiesIBA 01/2023 - 09/2020
3	Messenger RNA (mRNA)IBA 01/2023 - 01/2022
3	ErbB Receptors (EGF Receptor)IBA 06/2022 - 04/2018
3	Proteins (Proteins, Gene)FDA Link 04/2022 - 01/2018
3	Gemcitabine FDA Link 01/2021 - 01/2016
3	IodineIBA 01/2021 - 09/2018
3	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2021 - 02/2015
3	S-1 plus cisplatinIBA 06/2015 - 07/2009
3	GSK 1363089IBA 10/2013 - 08/2012
2	HLA Antigens (Human Leukocyte Antigens)IBA 01/2023 - 01/2016
2	Carboplatin (JM8)FDA LinkGeneric 01/2023 - 08/2019
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 06/2022 - 08/2012
2	regorafenibIBA 06/2022 - 02/2021
2	BNT162 VaccineIBA 04/2022 - 01/2022
2	COVID-19 VaccinesIBA 04/2022 - 01/2022
2	Proto-Oncogene Proteins c-kit (Proto-Oncogene Protein c-kit)IBA 01/2021 - 01/2018
2	Serum AlbuminIBA 01/2019 - 04/2018
2	AlbuminsIBA 01/2019 - 04/2013
2	Phenobarbital (Luminal)FDA Link 05/2018 - 07/2014
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 04/2018 - 01/2016
2	Trastuzumab (Herceptin)FDA Link 01/2018 - 08/2012
2	Methotrexate (Mexate)FDA LinkGeneric 01/2017 - 11/2016
2	CreatinineIBA 02/2016 - 03/2013
2	Inulin FDA Link 02/2016 - 03/2013
2	5- ((2,6- dichlorobenzyl)sulfonyl)- 3- ((3,5- dimethyl- 4- ((2- (pyrrolidin- 1- ylmethyl)pyrrolidin- 1- yl)carbonyl)- 1H- pyrrol- 2- yl)methylene)- 1,3- dihydro- 2H- indol- 2- oneIBA 10/2013 - 01/2013
2	Thyroid HormonesIBA 10/2013 - 06/2012
1	binimetinibIBA 02/2024
1	Dihydrotachysterol (AT 10)IBA 02/2024
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 02/2024
1	encorafenibIBA 02/2024

Therapy/Procedure

25	Chemoradiotherapy 03/2024 - 07/2009
22	Drug Therapy (Chemotherapy) 01/2023 - 02/2008
21	Therapeutics 11/2022 - 06/2012
19	Radiotherapy 03/2024 - 02/2008
4	Induction Chemotherapy 02/2021 - 02/2008
4	Neck Dissection (Radical Neck Dissection) 04/2019 - 08/2017
2	Lymph Node Excision (Lymph Node Dissection) 11/2023 - 01/2019
2	Drug Tapering 01/2022 - 09/2018
2	Immunotherapy 10/2021 - 09/2020
2	Genomic Medicine 07/2021 - 02/2021
2	Aftercare (After-Treatment) 12/2020 - 04/2018
2	Glossectomy 04/2019 - 12/2018
1	Tracheostomy 11/2023
1	Thyroidectomy 11/2023